+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Chronic Kidney Disease (CKD) Drugs: Global Strategic Business Report

  • PDF Icon

    Report

  • 179 Pages
  • October 2022
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309398

Global Chronic Kidney Disease (CKD) Drugs Market to Reach $16.9 Billion by 2027

In the changed post COVID-19 business landscape, the global market for Chronic Kidney Disease (CKD) Drugs estimated at US$12.9 Billion in the year 2020, is projected to reach a revised size of US$16.9 Billion by 2027, growing at a CAGR of 4% over the analysis period 2020-2027. Antihypertensives, one of the segments analyzed in the report, is projected to record a 4% CAGR and reach US$5.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Calcium Channel Blockers segment is readjusted to a revised 2.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $3.5 Billion, While China is Forecast to Grow at 6.4% CAGR

The Chronic Kidney Disease (CKD) Drugs market in the U.S. is estimated at US$3.5 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$3.4 Billion by the year 2027 trailing a CAGR of 6.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.3% and 3.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.2 Billion by the year 2027.

Erythropoiesis-Stimulating Agents (ESAs) Segment to Record 5.2% CAGR

In the global Erythropoiesis-Stimulating Agents (ESAs) segment, USA, Canada, Japan, China and Europe will drive the 5.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.5 Billion in the year 2020 will reach a projected size of US$2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 5.6% CAGR through the analysis period.

Select Competitors (Total 11 Featured) -

  • AbbVie, Inc.
  • Allergan PLC
  • Amgen, Inc.
  • AstraZeneca PLC
  • F. Hoffmann-La Roche AG
  • FibroGen, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Keryx Biopharmaceuticals, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.

What's New for 2022?

  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and a Research Platform
  • Complimentary updates for one year
Frequently Asked Questions about the Global Market for Chronic Kidney Disease (CKD) Drugs

What is the estimated value of the Global Market for Chronic Kidney Disease (CKD) Drugs?

The Global Market for Chronic Kidney Disease (CKD) Drugs was estimated to be valued at $12.9 Billion in 2020.

What is the growth rate of the Global Market for Chronic Kidney Disease (CKD) Drugs?

The growth rate of the Global Market for Chronic Kidney Disease (CKD) Drugs is 3.9%, with an estimated value of $16.9 Billion by 2027.

What is the forecasted size of the Global Market for Chronic Kidney Disease (CKD) Drugs?

The Global Market for Chronic Kidney Disease (CKD) Drugs is estimated to be worth $16.9 Billion by 2027.

Who are the key companies in the Global Market for Chronic Kidney Disease (CKD) Drugs?

Key companies in the Global Market for Chronic Kidney Disease (CKD) Drugs include AbbVie, Inc., Allergan PLC, Amgen, Inc., AstraZeneca PLC, F. Hoffmann, La Roche AG, FibroGen, Inc., GlaxoSmithKline PLC and Keryx Biopharmaceuticals, Inc..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Chronic Kidney Disease (CKD) Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Chronic Kidney Disease (CKD) Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027
  • Table 4: World Recent Past, Current & Future Analysis for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for Calcium Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
  • Table 7: World Recent Past, Current & Future Analysis for Antihypertensives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Antihypertensives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Antihypertensives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
  • Table 10: World Recent Past, Current & Future Analysis for Erythropoiesis-Stimulating Agents (ESAs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for Erythropoiesis-Stimulating Agents (ESAs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for Erythropoiesis-Stimulating Agents (ESAs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
  • Table 13: World Recent Past, Current & Future Analysis for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 15: World 15-Year Perspective for Beta Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
  • Table 16: World Recent Past, Current & Future Analysis for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 17: World Historic Review for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 18: World 15-Year Perspective for ACE Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
  • Table 19: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 20: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 21: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
  • Table 22: World Chronic Kidney Disease (CKD) Drugs Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027
III. MARKET ANALYSIS
UNITED STATES
  • Chronic Kidney Disease (CKD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
  • Table 23: USA Recent Past, Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 24: USA Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 25: USA 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes for the Years 2012, 2021 & 2027
CANADA
  • Table 26: Canada Recent Past, Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 27: Canada Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 28: Canada 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes for the Years 2012, 2021 & 2027
JAPAN
  • Chronic Kidney Disease (CKD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
  • Table 29: Japan Recent Past, Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 30: Japan Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 31: Japan 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes for the Years 2012, 2021 & 2027
CHINA
  • Chronic Kidney Disease (CKD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
  • Table 32: China Recent Past, Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 33: China Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 34: China 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes for the Years 2012, 2021 & 2027
EUROPE
  • Chronic Kidney Disease (CKD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
  • Table 35: Europe Recent Past, Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 36: Europe Historic Review for Chronic Kidney Disease (CKD) Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 37: Europe 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027
  • Table 38: Europe Recent Past, Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 39: Europe Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 40: Europe 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes for the Years 2012, 2021 & 2027
FRANCE
  • Chronic Kidney Disease (CKD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
  • Table 41: France Recent Past, Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 42: France Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 43: France 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes for the Years 2012, 2021 & 2027
GERMANY
  • Chronic Kidney Disease (CKD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
  • Table 44: Germany Recent Past, Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 45: Germany Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 46: Germany 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes for the Years 2012, 2021 & 2027
ITALY
  • Table 47: Italy Recent Past, Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 48: Italy Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 49: Italy 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes for the Years 2012, 2021 & 2027
UNITED KINGDOM
  • Chronic Kidney Disease (CKD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
  • Table 50: UK Recent Past, Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 51: UK Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 52: UK 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes for the Years 2012, 2021 & 2027
SPAIN
  • Table 53: Spain Recent Past, Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 54: Spain Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 55: Spain 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes for the Years 2012, 2021 & 2027
RUSSIA
  • Table 56: Russia Recent Past, Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 57: Russia Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 58: Russia 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes for the Years 2012, 2021 & 2027
REST OF EUROPE
  • Table 59: Rest of Europe Recent Past, Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 60: Rest of Europe Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 61: Rest of Europe 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes for the Years 2012, 2021 & 2027
ASIA-PACIFIC
  • Chronic Kidney Disease (CKD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
  • Table 62: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 63: Asia-Pacific Historic Review for Chronic Kidney Disease (CKD) Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 64: Asia-Pacific 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027
  • Table 65: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 66: Asia-Pacific Historic Review for Chronic Kidney Disease (CKD) Drugs by Drug Class - Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 67: Asia-Pacific 15-Year Perspective for Chronic Kidney Disease (CKD) Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers and Other Drug Classes for the Years 2012, 2021 & 2027
AUSTRALIA
  • Chronic Kidney Disease (CKD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)
INDIA
  • Chronic Kidney Disease (CKD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Chronic Kidney Disease (CKD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Chronic Kidney Disease (CKD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Chronic Kidney Disease (CKD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie, Inc.
  • Allergan PLC
  • Amgen, Inc.
  • AstraZeneca PLC
  • F. Hoffmann-La Roche AG
  • FibroGen, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Keryx Biopharmaceuticals, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.